Biotech

AstraZeneca unit defeats Soliris antitrust suit over biosimilar delays
17 November 2026   A US judge tosses an antitrust lawsuit accusing Alexion of using sham patent litigation to delay competition to Soliris, finding that its favourable settlement with a rival undermined the claims.

More News

28 October 2026   Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.
16 October 2026   All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.
14 October 2026   Growing demand from life sciences and healthcare clients prompts an expansion in California, bringing the firm closer to biotechnology companies, research institutions and key courts for its Southern California litigators.
1 October 2026   With patent validity increasingly being fought over in both the UPC and EPO, Genevant Sciences’ Stephan Kutik talks to LSIPR about keeping parallel proceedings aligned and why teamwork matters.
29 September 2026   The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.
23 September 2026   Varnum appoints the new partner to its litigation and ADR practice team as a partner in Michigan, bringing industry expertise in software, medical devices, robotics, consumer electronics and more.
More news


Latest Features

Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotech
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
All features